• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Talis Biomedical Corporation

    9/20/24 8:57:32 AM ET
    $TLIS
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $TLIS alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 333-252360
    Issuer: Talis Biomedical Corp
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 230 Constitution Drive
    Menlo Park CALIFORNIA 94025
    Telephone number: 650-433-3023
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Common stock
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2024-09-20 By Aravind Menon Hearings Advisor
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TLIS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TLIS

    DatePrice TargetRatingAnalyst
    1/7/2022$3.00Neutral → Underperform
    BofA Securities
    9/27/2021$10.00 → $7.00Neutral → Underweight
    JP Morgan
    8/31/2021Buy → Neutral
    BTIG Research
    8/12/2021$9.00Overweight → Neutral
    Piper Sandler
    8/11/2021$17.00 → $10.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $TLIS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash

      REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. While the Company has made progress developing the Talis One® system, it believes that this is a prudent path forward given current market conditions. As part of this process, the Company's Board of Directors has appointed a special committee of independent, disinterested directors to consider a

      11/14/23 8:00:00 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update

      REDWOOD CITY, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the second quarter ended June 30, 2023, and provided a business update. Recent Business Highlights Initiated clinical study to support COVID-19 510(k) submission for clearance of the Talis One® systemPresented positive data at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) annual meeting differentiating the planned Talis One test menu Development-stage chlamy

      8/10/23 4:05:00 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023

      REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). The live webcast of the event may be accessed by registering online for dial-in information via the News & Events page of the investor section o

      8/3/23 8:00:00 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TLIS
    Financials

    Live finance-specific insights

    See more
    • Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash

      REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. While the Company has made progress developing the Talis One® system, it believes that this is a prudent path forward given current market conditions. As part of this process, the Company's Board of Directors has appointed a special committee of independent, disinterested directors to consider a

      11/14/23 8:00:00 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023

      REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). The live webcast of the event may be accessed by registering online for dial-in information via the News & Events page of the investor section o

      8/3/23 8:00:00 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Talis Biomedical to Provide Business Update and Financial Results on May 11, 2023

      REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will provide a business update and financial results on Thursday, May 11, 2023, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). The live webcast of the event may be accessed by registering online for dial-in information via the News & Events page of the investor section of Talis Biomedical's w

      5/4/23 8:00:00 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TLIS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Leonard Braden Michael bought $44,240 worth of shares (30,100 units at $1.47) (SEC Form 4)

      4 - Talis Biomedical Corp (0001584751) (Issuer)

      9/9/24 4:24:12 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Large owner Leonard Braden Michael bought $2,000 worth of shares (500 units at $4.00) (SEC Form 4)

      4 - Talis Biomedical Corp (0001584751) (Issuer)

      9/5/24 11:57:28 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Large owner Leonard Braden Michael bought $642 worth of shares (151 units at $4.25) (SEC Form 4)

      4 - Talis Biomedical Corp (0001584751) (Issuer)

      9/4/24 8:19:50 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TLIS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Leonard Braden Michael bought $44,240 worth of shares (30,100 units at $1.47) (SEC Form 4)

      4 - Talis Biomedical Corp (0001584751) (Issuer)

      9/9/24 4:24:12 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Large owner Leonard Braden Michael bought $2,000 worth of shares (500 units at $4.00) (SEC Form 4)

      4 - Talis Biomedical Corp (0001584751) (Issuer)

      9/5/24 11:57:28 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Large owner Leonard Braden Michael bought $642 worth of shares (151 units at $4.25) (SEC Form 4)

      4 - Talis Biomedical Corp (0001584751) (Issuer)

      9/4/24 8:19:50 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TLIS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Talis Biomedical Corporation

      SC 13D/A - Talis Biomedical Corp (0001584751) (Subject)

      10/10/24 5:01:39 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Talis Biomedical Corporation

      SC 13G/A - Talis Biomedical Corp (0001584751) (Subject)

      8/14/24 9:23:03 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Talis Biomedical Corporation

      SC 13G - Talis Biomedical Corp (0001584751) (Subject)

      8/14/24 8:44:42 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TLIS
    Leadership Updates

    Live Leadership Updates

    See more
    • Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)

      REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (POC), today announced that it has appointed Dr. Andrew A. Lukowiak as president and chief scientific officer, effective August 1, 2023. Dr. Lukowiak has more than 20 years of senior leadership experience in the clinical diagnostics industry at both publicly traded and privately held commercial-stage companies. As a member of the executive leadership team, he will be responsible for leading the assay development, platf

      8/2/23 8:00:00 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent Director

      REDWOOD CITY, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced Heiner Dreismann has joined its board of directors, effective immediately. Talis Bio also recently appointed Kim Popovits, who has served as a member of the board since March 2020, as its lead independent director. "Heiner's entrepreneurial vision and track record leading multiple corporate functions over the course of his 20-year tenure at Roche Diagnostics are ideal for the opportunities Talis Bio is

      5/23/23 8:00:00 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Talis Biomedical Announces Leadership Transition

      MENLO PARK, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that Rob Kelley, the Company's current Chief Commercial Officer, has been promoted to Chief Executive Officer and Director, effective immediately. Brian Blaser has stepped down from the positions of President, Chief Executive Officer and Director, due to personal matters. About Rob KelleyMr. Kelley has more than 25 years of leadership experience in the biotechnology industry and has served as the Company's Chief Co

      12/8/21 8:00:00 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TLIS
    SEC Filings

    See more
    • SEC Form 15-12G filed by Talis Biomedical Corporation

      15-12G - Talis Biomedical Corp (0001584751) (Filer)

      9/30/24 6:05:56 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 25-NSE filed by Talis Biomedical Corporation

      25-NSE - Talis Biomedical Corp (0001584751) (Subject)

      9/20/24 8:57:32 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Talis Biomedical Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Talis Biomedical Corp (0001584751) (Filer)

      9/17/24 4:11:46 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TLIS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Talis Biomedical downgraded by BofA Securities with a new price target

      BofA Securities downgraded Talis Biomedical from Neutral to Underperform and set a new price target of $3.00

      1/7/22 8:55:21 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Talis Biomedical downgraded by JP Morgan with a new price target

      JP Morgan downgraded Talis Biomedical from Neutral to Underweight and set a new price target of $7.00 from $10.00 previously

      9/27/21 5:04:24 AM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Talis Biomedical downgraded by BTIG Research

      BTIG Research downgraded Talis Biomedical from Buy to Neutral

      8/31/21 3:31:48 PM ET
      $TLIS
      Biotechnology: Laboratory Analytical Instruments
      Industrials